Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay

Table 2 Demographics of patients who provided samples for analysis

Patient	Sample type	Sample age, years	Patient age at surgery, years	Sex	Primary diagnosis	Clinical stage
NSCLC
1	Lung	9	79	Male	Squamous cell carcinoma	II
2	Lung	2	50	Male	Squamous cell carcinoma	IIIA
3	Lung	1	82	Male	Adenocarcinoma	IIB
4	Lung	13	70	Female	Adenocarcinoma	IB
5	Lung	13	71	Male	Squamous cell carcinoma	IIA
HNSCC
6	Tonsil	10	64	Female	Squamous cell carcinoma	I
7	Tongue	9	71	Female	Squamous cell carcinoma	I
8	Larynx	6	55	Male	Squamous cell carcinoma	III
9	Tonsil	6	49	Female	Squamous cell carcinoma	I
10	Tongue	3	68	Male	Squamous cell carcinoma	I
UC
11	Bladder	7	74	Female	Urothelial cell carcinoma	III
12	Bladder	4	70	Male	Urothelial cell carcinoma	II
13	Bladder	4	67	Male	Urothelial cell carcinoma	IV
14	Bladder	3	80	Female	Urothelial cell carcinoma	III
15	Bladder	3	82	Male	Urothelial cell carcinoma	III

HNSCC head and neck squamous cell carcinoma, NSCLC non-small cell lung cancer, UC urothelial carcinoma

ISSN: 1746-1596